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Methamphetamine (METH) is a psychostimulant drug of abuse that produces long-term behavioral changes including behavioral
sensitization, tolerance, and dependence. METH has been reported to induce neurotoxic eﬀects in several areas of the brain
via the dopaminergic system. Changes of dopamine function can induce malfunction of the glutamatergic system. Therefore,
the aim of the present study was to examine the eﬀects of METH administration on the expression of glutamate N-methyl-
D-aspartate receptor subunit 1 (NMDAR1) in frontal cortex, striatum, and hippocampal formation after acute and subacute
exposure to METH by western blotting. Male Sprague-Dawley rats were injected intraperitoneally with a single dose of 8mg/kg
METH, 4mg/kg/day METH for 14 days and saline in acute, subacute, and control groups, respectively. A signiﬁcant increase in
NMDAR1 immunoreactive protein was found in frontal cortex in the subacute group (P = .036) but not in the acute group
(P = .580). Moreover, a signiﬁcant increase in NMDAR1 was also observed in striatum in both acute (P = .025) and subacute
groups (P = .023). However, no signiﬁcant diﬀerences in NMDAR1 in hippocampal formation were observed in either acute or
subacute group. The results suggest that an upregulation of NMDA receptor expression may be a consequence of glutamatergic
dysfunction induced by METH.
Copyright © 2009 Walailuk Kerdsan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Methamphetamine (METH), an N-methyl homolog of
amphetamine, is an addictive psychostimulant with potent
eﬀects on the central nervous system, resulting in behavioral
changes including sensitization, tolerance, and dependence
[1]. Neurochemical studies have shown long-term neuro-
toxic eﬀects of METH on monoamine neurotransmitters
including dopamine [2], serotonin, and norepinephrine [3]
systems in several brain regions. Moreover, many studies
havesuggestedthatnotonlyaremonoaminesystemsaﬀected
by METH-induced neurotoxicity, but the glutamatergic
system has also been involved in the toxic eﬀect of METH
[4, 5].
Several studies support the role of glutamate in the
development of METH toxicity. METH enhances glutamate
release in several brain regions, such as striatum [6],
cerebral cortex [7], hippocampus [8], ventral tegmental
area, and nucleus accumbens [9]. An elevation of extra-
cellular glutamate can activate glutamate receptors which
may mediate excitotoxicity leading to apoptosis and/or
neuronal cell death [10]. With Glutamate/N-methyl-D-
aspartate (NMDA) receptors, which play a principle role
in excitatory neurotransmission, brain development, and
synaptic plasticity, have been reported to be implicated
in METH neurotoxicity [11]. Furthermore, a reduction of
glutamate/NMDA receptors has been reported in substantia
nigra, nucleus accumbens, and medial prefrontal cortex
during amphetamine withdrawal [12]. These observations
suggest that glutamate/NMDA receptors may play a critical
role in the eﬀects of drug addiction. However, the neuro-
chemical and behavioral consequences of METH depend
on the extent and route of exposure to the drug [13].
Changes in NMDA receptors seem to be related to the2 Journal of Biomedicine and Biotechnology
administration model and doses of METH [12, 14]. It is,
therefore, important to study eﬀects on the glutamatergic
system,particularlyNMDAreceptors,underlyingthepattern
of exposure to METH. Therefore, the aim of the present
study was to investigate the eﬀects of acute and subacute
METH administration in an exposure pattern of single
daily injection on the alteration of NMDA receptor subunit
1 immunoreactivity in rat striatum, frontal cortex and
hippocampal formation.
2.MaterialsandMethods
Male Sprague-Dawley rats (250–280g) were obtained from
the National Animal Center, Mahidol University, Thailand.
The animals were housed 2-3 per cage and maintained at
24 ± 1◦C under a 12-hour light/dark cycle with free access
to water and food. All animal procedures were carried out
in compliance with Mahidol University Code of Practice
and the National Institutes of Health (USA) Guidelines
for treatment of laboratory animals. The protocol for this
study was approved by the Animal Research Committee of
Naresuan University, Thailand.
Drug treatment consisted of D-methamphetamine HCl
(Alltech, Ill, USA) with permission of Ministry of Public
Health. Animals in the acute METH group received vehicle
for13daysandfollowedbyoneinjectionofMETH(8mg/kg,
I P )o nd a y1 4 .A n i m a l sw e r et r e a t e dw i t hM E T Hf o r1 4
days (4mg/kg/day, IP) in the subacute group. For the control
group, animals were treated with vehicle for 14 days. All rats
were decapitated at 24-hour after the last dose. The striatum,
frontalcortexandhippocampalformationwereisolated,and
t i s s u e sw e r es t o r e da t−70
◦C until used.
NMDA receptor subunit 1 immunoreactivity
(NMDAR1-IR) was determined following the method
previously reported [15]. Brieﬂy, tissue was homogenized
in 5 mM Tris-HCl containing 20mM NaCl, pH 8.0, and
the homogenate was then centrifuged. The pellet was
homogenized again in lysis buﬀer. Protein concentration
in the tissue lysate was estimated by the bicinchoninic
acid assay (BCA) (Pierce, Ill, USA). Tissue lysate was
then boiled for 5minutes with an equal volume of
2x sample buﬀer. The supernatants containing 50μg
original proteins, chosen to give results within the linear
range for NMDAR1 estimations, were separated by
polyacrylamide gel electrophoresis. The proteins were then
electrotransferred onto polyvinylidene ﬂuoride (PVDF)
membranes (Amersham, Ill, USA). Membranes were
incubated with protein blocking solution and subsequently
incubated with NMDAR1 antibody (Sigma-Aldrich,
Mo, USA). The membranes were then incubated with
biotinylated secondary antibody (Vector, Calif, USA) and
avidin biotinylated horseradish peroxidase complexes (ABC
kit) (Vector, Calif, USA). The protein immunoreactivity
was visualized using 3,3 ,5,5 -tetramethylbenzidine (TMB)
(Promega, USA). Immunoblotting for β-actin (Santa Cruz,
Calif, USA) was used as an internal standard to conﬁrm
equal protein loading and sample transferring. Expression of
NMDAR1 protein was normalized against that of β-actin.
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Figure 1: Expression of NMDAR1 in striatum. Data are integrated
optical density of NMDAR1 immunoreactivity band, normalized
to β-actin levels, and expressed as percentage of the control group.
Values represent mean ± S.E.M (n = 5–7). ∗P<. 05 in comparison
with the control group by one-way ANOVA with Dunnett post-hoc
test.
The immunostained membranes were scanned into a
computer and integrated optical density (IOD) was mea-
sured by Scion Image program based on NIH image (v.
Alpha 4.0.3.2; http://www.scioncorp.com; 2000-2001). The
value is the sum of the optical densities of all pixels in the
region. All immunoreactive bands were measured with the
same dimensions to obtain their integrated optical density.
Data were expressed as percentage of control group and all
data were represented as mean ± S.E.M. Diﬀerences between
groups were analyzed using ANOVA followed by Dunnett
post-hoc test.
3. Results
Immunostaining for NMDAR1 consistently demonstrated
an immunoreactive band corresponding to approximately
116kDa and a β-actin immunoreactive band was approx-
imately 43kDa. Densitometric analysis was performed to
quantify the alteration of NMDAR1 expression relative
to β-actin immunoreactivity. ANOVA demonstrated that
NMDAR1-IR was signiﬁcantly increased above control in
the striatum after both acute (P = .025) and subacute
(P = .023) METH administration, and reached 196% and
198% of control group, respectively (Figure 1). Moreover, a
signiﬁcant increase of NMDAR1-IR (508% over control) was
also observed in the frontal cortex in the subacute METH
(P = .036), but not in the acute group (P = .580) (Figure 2).
However, there were no signiﬁcant diﬀerences of NMDAR1-
IR in the hippocampal formation either in acute (P = .839)
or subacute (P = .711) METH groups when compared with
the control group (Figure 3).
4. Discussion
The present study revealed that single daily exposure to
METH can induce a signiﬁcant increase of NMDAR1-IR
in the cortical and subcortical regions of rat brain. The
eﬀect was observed in the frontal cortex after subacuteJournal of Biomedicine and Biotechnology 3
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Figure 2: Expression of NMDAR1 in frontal cortex. Data are
integrated optical density of NMDAR1 immunoreactivity band,
normalized to β-actin levels and expressed as percentage of the
control group. Values represent mean ± S.E.M (n = 5–7). ∗P<. 05
in comparison with the control group by one-way ANOVA with
Dunnett post-hoc test.
0
20
40
60
80
100
120
140
160
I
O
D
(
%
o
f
c
o
n
t
r
o
l
)
Control Acute Subacute
Hippocampal formation
Figure 3: Expression of NMDAR1 in hippocampal formation. Data
are integrated optical density of NMDAR1 immunoreactivity band,
normalized to β-actin levels and expressed as percentage of the
control group. Values represent mean ± S.E.M (n = 5–7).
METH administration. Moreover, the results showed an up-
regulation of NMDAR1 in the striatum after both acute and
subacute METH administrations. As METH is an abused
psychostimulant, our results provide a support for eﬀects
of these drugs on glutamatergic systems. Glutamatergic
dysfunctions may be a consequence of changes in the
dopaminergic system induced by psychostimulants [16].
Moreover, an impairment of monoamine neurotransmission
after repeated METH exposure can produce changes in
amino acid homeostasis, potentially leading to neurotoxicity
[17].
The results of this study are in agreement with previous
reports of elevated NMDA receptor binding in cerebral
cortex following both psychostimulants METH [18]a n d
cocaine [19], suggesting the involvement of the NMDA
receptor in the development of drug addiction.
Supporting a hypothesis of glutamatergic dysfunction in
cortical and subcortical regions following psychostimulant
drug exposure, we previously observed an upregulation of
NMDAR1 density in dentate gyrus following administration
of pseudoephedrine, a drug which is considered to be
a psychostimulant [20]. Moreover, increased metabotropic
glutamate receptor (mGluR5) protein and gene expression
have been reported in cultured cortical and hippocampal
neuronsafteramphetamineadministration[21].Anincrease
in vesicular glutamate transporter (VGLUT1), an important
component of glutamatergic neurons that regulates glu-
tamate release, has been observed in striatal and cortical
regions after METH administration, supporting evidence for
METH-induced elevation of glutamate release in striatum
and cortex [6].
Although no alteration in NMDAR1-IR in the hip-
pocampal formation was observed in the present study after
METH treatment, the ﬁnding is consistent with a previous
study that revealed a slight decrease in NMDAR1 mRNA
expression in dentate gyrus after exposure to cocaine [22].
Moreover, no diﬀerences in the NMDAR1, 2A and 2B
immunoreactivities were observed in the hippocampus of
METH-sensitized rats [23]. Taken together, our observations
provide further support for the regional speciﬁcity of
glutamatergic dysfunction after METH administration.
In summary, our results indicate an upregulation of
NMDA receptor expression after acute and subacute expo-
sure to METH reﬂecting the dysfunction of glutamatergic
system. The alterations in the NMDAR1 found in the
striatum and frontal cortex suggest that other components
of the glutamate synapse may be abnormal in these regions
in METH dependence. Further work is still needed to study
other components of glutamatergic neurotransmission in
order to investigate abnormalities of glutamatergic system in
METH dependence.
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